What We Do
Founded in 2008, Astraea Therapeutics is a privately-held biopharmaceutical company, specializing in novel approaches, with small-molecule therapeutics, for the treatment of drug addiction and central nervous system disorders, including pain and neurodegenerative diseases.
Astraea’s core competencies in innovative drug discovery result from deep, long-standing expertise in novel target validation, creation of new molecular entities and intellectual property, well-defined translational development, and a mission to develop life-changing medications for unmet needs in CNS disorders.
Astraea’s medication discovery focuses on two novel pharmacological targets, which have the potential to deliver transformative treatments for the opioid crisis, chronic pain therapy, and smoking cessation relapse.
Dr. Nurulain T. Zaveri, PhD
Founder and Chief Scientific Officer
Nurulain Zaveri is the Founder, President and Chief Scientific Officer of Astraea Therapeutics, a preclinical discovery company she founded in 2009, whose mission is medication development for under-served diseases of the central nervous system (such as opioid and substance abuse and addiction, chronic pain and Parkinson’s disease). A PhD medicinal chemist by training, Dr. Zaveri is a recognized expert in the field of G-protein coupled receptor-targeted- and ion channel-targeted drug discovery for CNS medications. Pioneering discoveries from her laboratory have contributed to the understanding of the pharmacology of drug addiction and pain, and are being advanced into medication development.